Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.

Also called NCT03749057

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 400 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03749057
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03749057. Allocation not applicable; no masking; primary purpose treatment. Start 2018-11-20 (actual); primary completion 2025-03-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation
Acronym
ERSAF
Condition
Cerebral Infarction
Intervention (Drug)
Rivaroxaban
Lead sponsor
General Hospital of Shenyang Military Region (class: other)

Record details

Record id
cardio:ct-nct03749057
Content hash
9034bbf340dfa35740b49ac8e812c0a94ac9a798435c2744642918fad760f9f0